Nonsteroidal targeted analgesics
【Indications】
1.Analgesia in post-operation and cancer.
【Specifications】5ml∶50mg
【Product advantage】
1. National Health Insurance Drug List B Product
2. Targeted analgesia, higher security
Antihypertensive agent (New short - acting dihydropyridine calcium channel antagonist)
【Indications】
1. Oral treatment of ineffective hypertension.
【Specifications】50ml∶25mg
【Product advantage】
1. The first dihydropyridine calcium channel blocker for intravenous injection
2. High blood vessel and myocardial selectivity
3. No active metabolites
short-acting, non-depolarizing skeletal muscle relaxant
【Indications】
1. Mivacurium chloride Injection is a high-selectivity, short-acting and non-depolarizing neuromuscular blocking agent, and it has the characteristics of fast recovery after action.
2. Mivacurium chloride Injection can act as an adjunct to general anesthesia, providing skeletal muscle relaxation to facilitate tracheal intubation and mechanical ventilation.
【Specifications】5ml:10mg
【Product advantage】
1. National Health Insurance Drug List B Product
2. Short-acting & non-depolarzing skeletal muscle relaxant
3. Take effect rapidly, short lasting duration, recover quickly, without cumulative effect
4. Fewer adverse reaction on vegetative nerve and cardiovascular
5. Mivacurium chloride Injection is the only non-depolarzing skeletal
muscle relaxant that does not require anticholinesterase antagonism.
6. The neurotoxicity of mivacurium chloride is apparently inferior to cis-atracurium.